Guangzheng Group Co Ltd

Guangzheng Eye Hospital released its 2026 interim report, with net profit attributable to the parent company of 17.7758 million yuan. The company's total operating revenue was 390 million yuan, down 10.55 percent from the same period last year, a decrease of 46.0085 million yuan. Net cash inflow from operating activities was 31.3027 million yuan. The latest asset-liability ratio was 90.19 percent, gross margin was 39.88 percent, and return on equity was 15.80 percent. Diluted earnings per share were 0.03 yuan, total asset turnover was 0.34 times, and inventory turnover was 8.85 times. The number of shareholders was 37,100, and the top ten shareholders held 30.92 percent of total share capital.

A wholly owned subsidiary of Guangzheng Eye Hospital Group, Guangzheng Construction Group, has taken Nantong No.4 Construction Group and the Eighth Affiliated Hospital of Xinjiang Medical University to court over unpaid construction fees, with the amount involved totaling approximately 26.27 million yuan. After Guangzheng Construction completed the work as a subcontractor, Nantong No.4 Construction failed to pay the outstanding fees. The lawsuit seeks an order for Nantong No.4 Construction to pay 23.55 million yuan in overdue construction fees and 2.71 million yuan in late payment interest, and also asks that the Eighth Affiliated Hospital of Xinjiang Medical University bear payment liability within the scope of the fees it owes to Nantong No.4 Construction. The case has been accepted but has not yet been heard, and the company says it cannot currently assess the specific financial impact. Notably, Guangzheng Eye Hospital reported a net loss attributable to the parent of 19.50 million yuan for 2025, meaning the amount at stake in this lawsuit already exceeds the full-year loss. Moreover, the company's net profit after deducting non-recurring items has been negative for 13 consecutive years from 2013 to 2025.

Guangzheng Eye Care granted 1.5 million restricted shares to 103 incentive recipients at a grant price of 1.84 yuan per share. The company disclosed the incentive plan in an announcement on July 28, detailing the allocation of shares among the recipients. In addition, in the first quarter of 2026, Guangzheng Eye Care achieved revenue of 187 million yuan, with a net loss attributable to the parent company of 3.84 million yuan.